Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Beta-hematin is the synthetic analogue of hemozoin, a dark-brown biocrystal produced by hematophagous parasites such as Plasmodium falciparum to detoxify free heme. During the intraerythrocytic stage of malaria, the parasite digests host hemoglobin, releasing large quantities of toxic ferriprotoporphyrin IX (heme). To prevent oxidative damage and membrane disruption, the parasite sequesters this heme into insoluble beta-hematin crystals within its acidic food vacuole. This crystallization process is a critical survival mechanism and serves as a primary target for several classes of antimalarial drugs, most notably the quinolines. Drugs like chloroquine bind to the growing faces of the crystals or to free heme, preventing further polymerization and resulting in the accumulation of toxic heme that kills the parasite. Understanding the formation of beta-hematin is essential for developing new treatments against drug-resistant malaria strains.
Inhibition of heme crystallization into beta-hematin, leading to the accumulation of toxic free ferriprotoporphyrin IX which causes parasite cell death.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Beta-hematin (BH).